The EVEREST-2 study reported the first complete response to CAR-T cell therapy in a non-small cell lung cancer patient.

Lyell Immunopharma, Inc. announced new clinical data from the ongoing Phase 1/2 trial of its CAR T-cell product, LYL314, designed to treat relapsed/refractory large B-cell lymphoma. The company has ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient ...

During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.

CAR-T cell therapy provides long, treatment-free remissions for relapsed multiple myeloma, using genetically modified T cells ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

The global car-t cell therapy market was valued at USD 5.2 billion in 2024 and is projected to reach USD 26.2 billion by 2030, expected to grow at a CAGR of 31 % during the forecast period, 2025-2030.

Qihan Biotech Presents New Clinical Data on Allogeneic CAR-T Cell Therapies and Preclinical Data on In Vivo CAR-T at the American Society of Hematology (ASH) Annual Meeting – Clinical data from ...

SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, ...

Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...